(January 11, 2022, 1:31 PM EST) -- ALEXANDRIA, Va. — In a Jan. 7 petition for inter partes review filed with the Patent Trial and Appeal Board, a clinical stage ophthalmic company seeks cancellation of various claims of a patented method for treating the progression of myopia through the administration of low-concentration ophthalmic atropine solutions....